The United States District Court in Boston has entered final judgment ending the five-year patent infringement dispute between Amgen and Roche prohibiting Roche from infringing Amgen’s patents on recombinant erythropoietin (EPO). The judgment was accompanied by Roche’s admission that the five Amgen EPO patents involved in the lawsuit were infringed by Roche’s pegylated-erythropoietin (peg-EPO) product, Mircera. Amgen will allow Roche to begin selling Mircera in the U.S. in mid-...